argenx SE announced the FDA approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized… read more.
Bristol Myers Squibb announced that the FDA has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA). Sotyktu, an oral, selective tyrosine kinase 2… read more.
A new paper in Rheumatology Advances in Practice, published by Oxford University Press, indicates that Tik Tok videos about gout are commonly misleading, inconsistent, or inaccurate. Gout is a painful… read more.
Sandoz announced the European launch of Wyost (denosumab 120 mg) and Jubbonti (denosumab 60 mg). The medicines are among the first denosumab biosimilars to launch in Europe and are approved… read more.
AbbVie announced positive topline results from the Phase IIIb/IV head-to-head SELECT-SWITCH study evaluating the efficacy and safety of upadacitinib (Rinvoq) 15 mg, once daily, compared to adalimumab (Humira)… read more.
Novartis announced plans to present data from 27 company- or investigator-sponsored abstracts across its Immunology portfolio and pipeline at the 2025 American College of Rheumatology (ACR) Convergence. Data… read more.
For patients with knee osteoarthritis, aerobic activities such as walking, cycling, or swimming are likely to be the best exercise for improving pain, function, gait performance, and quality… read more.
Sobi global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare disease, will be presenting new data across its immunology portfolio at the annual American College… read more.
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling… read more.
New research from The University of Texas at Arlington shows that differences in state welfare policies are linked to rising arthritis-related joint pain across much of the U.S…. read more.
A single course of low-dose radiation therapy may provide a safe and effective alternative treatment option for people with painful knee osteoarthritis according to a new randomized, placebo-controlled… read more.
Camurus announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Oczyesa, (octreotide subcutaneous depot), marketing authorization for the maintenance treatment in adult patients with… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
